A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 610
研究概览
简要总结
2012 Results article in http://www.ncbi.nlm.nih.gov/pubmed/22578446 results 2012 Results article in http://www.ncbi.nlm.nih.gov/pubmed/22555112 results 2013 Results article in http://www.ncbi.nlm.nih.gov/pubmed/23870813 results 2013 Results article in http://www.ncbi.nlm.nih.gov/pubmed/24070809 results 2014 Results article in http://www.ncbi.nlm.nih.gov/pubmed/25079928 results 2015 Results article in http://www.ncbi.nlm.nih.gov/pubmed/26445075 results 2016 Results article in http://www.ncbi.nlm.nih.gov/pubmed/27073205 results 2018 Results article in http://www.ncbi.nlm.nih.gov/pubmed/30555977 results 2019 Results article in http://www.ncbi.nlm.nih.gov/pubmed/30301555 results 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35314388/ 7-year follow-up (added 24/10/2022) 2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32359843/ Long-term visual outcomes (added 24/10/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adults age =50 of either sex
- •2. Newly referred for the treatment of CNV caused by Age-related Macular Degeneration (AMD) in the first or second eye
- •3. Corrected 1 metre logarithmic minimal angle resolution visual acuity (VAlogMAR) =25 letters read on a standard Early Treatment Diabetic Retinopathy Study (ETDRS) chart
- •4. CNV involving the centre of the fovea
- •If a fellow eye develops CNV from AMD, it will be treated with the optimal locally available treatment.
排除标准
- •1. Corrected 1 metre VAlogMAR <25 letters
- •2. Long standing CNV evidenced by the presence of fibrosis in excess of 50% of the total lesion
- •3. Presence of other active ocular disease causing concurrent vision loss, e.g. diabetic retinopathy
- •4. Previous treatment with PhotoDynamic Therapy (PDT) or a VEGF inhibitor in the eye being considered for inclusion